.Attributes Medication, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA research, after a typical consequence of 11 months, individuals with metastatic gastrointestinal lumps that got biomarker-matched therapies based on spreading tumor DNA profiling showed a higher clinical advantage than those getting unparalleled treatment.